Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 2Congenital Abnormalities 2Small Cell Lung Carcinoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1

Interventions

Cytarabine 22Mitoxantrone 7Etoposide 7Idarubicin 6tipifarnib 4Filgrastim 4Topotecan 3Sorafenib 3Lenalidomide 3Daunorubicin 3Cyclophosphamide 3Clofarabine 3Bortezomib 3Azacitidine 3veliparib 2tanespimycin 2fludarabine phosphate 2alvocidib 2Imatinib Mesylate 2Everolimus 2Carboplatin 2Arsenic Trioxide 2trebananib 1romidepsin 1perifosine 1octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate 1ispinesib 1entinostat 1eltrombopag 1choline magnesium trisalicylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myelomonocytic, Acute × Podophyllotoxin × Clear all
NCT01127009 2015-08-13

Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Case Comprehensive Cancer Center

Phase 1 Completed
3 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡